Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

eUpdate – Prostate Cancer Treatment Recommendations

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

Published online: 21 March 2023
K. Fizazi & S. Gillessen, et al., on behalf of the ESMO Guidelines Committee

  • Abiraterone acetate with prednisone improved MFS and OS for very-high-risk localised prostate cancer undergoing RT and ADT.
  • Combining ADT with docetaxel–abiraterone–prednisone in men with de novo mHSPC improved both rPFS and OS versus ADT–docetaxel.
  • Combining ADT with docetaxel and darolutamide in men with mHSPC improved OS versus ADT–docetaxel.
  • Olaparib improved OS in men with mCRPC and BRCA alterations post-novel androgen receptor axis inhibitor.
  • Cabazitaxel in men with mCRPC post-novel androgen receptor axis inhibitor and docetaxel improved both rPFS and OS.
  • 177Lu-PSMA-617 in men with mCRPC post-novel androgen receptor axis inhibitor and taxanes improved both rPFS and OS.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.